文献速递腹部US

基于超声造影的列线图:预测混合型肝细胞-胆管癌术后早期复发的潜在工具

Contrast-Enhanced Ultrasound-Based Nomogram: A Potential Predictor of Individually Postoperative Early Recurrence for Patients With Combined Hepatocellular-Cholangiocarcinoma.
PubMed 文献 · J Ultrasound Med · 2021-11-09

本研究评估超声造影(CEUS)对混合型肝细胞-胆管癌(CHC)术后复发的预测价值,并构建基于CEUS的早期复发预测列线图,与TNM分期比较。多因素分析显示CA19-9、凝血酶原时间、总胆红素、肿瘤形状及LI-RADS分类是独立因素;CEUS-临床列线图在3个月、6个月和1年AUC分别为0.518、0.552和0.843,校准曲线接近理想线,能有效分层高/低风险,而TNM分期仅在训练集有效。

要点

  • CEUS联合临床因素列线图可预测CHC术后3个月、6个月和1年复发风险。
  • LI-RADS LR-M类别患者无复发生存期长于LR-4/5类别。
  • 列线图风险分层能力优于TNM分期,尤其1年预测AUC达0.843。

关键影像表现/征象

  • 肿瘤形状是影响无复发生存期的独立因素。
  • LI-RADS LR-M类别患者无复发生存期长于LR-4/5类别。

诊断标准与关键数值

  • CEUS-临床列线图预测3个月、6个月和1年复发的AUC分别为0.518、0.552和0.843。

临床应用与阅片要点

  • 可将CEUS特征(肿瘤形状、LI-RADS分类)与临床因素结合用于CHC术后复发风险分层。
  • CEUS-临床列线图在不同预测时间点校准曲线接近理想线,提示预测概率与实际风险一致性较好。
  • CEUS-临床模型在训练集和验证集均能有效分层高/低复发风险,而TNM分期仅在训练集有效。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

PURPOSES: To evaluate the postsurgical prognostic implication of contrast-enhanced ultrasound (CEUS) for combined hepatocellular-cholangiocarcinoma (CHC). To build a CEUS-based early recurrence prediction classifier for CHC, in comparison with tumor-node-metastasis (TNM) staging.

METHODS: The CEUS features and clinicopathological findings of each case were analyzed, and the Liver Imaging Reporting and Data System categories were assigned. The recurrence-free survival associated factors were evaluated by Cox proportional hazard model. Incorporating the independent factors, nomograms were built to estimate the possibilities of 3-month, 6-month, and 1-year recurrence and whose prognostic value was determined by time-dependent receiver operating characteristics, calibration curves, and hazard layering efficiency validation, comparing with TNM staging system.

RESULTS: In the multivariable analysis, the levels of carbohydrate antigen 19-9, prothrombin time and total bilirubin, and tumor shape, the Liver Imaging Reporting and Data System category were independent factors for recurrence-free survival. The LR-M category showed longer recurrence-free survival than did the LR-4/5 category. The 3-month, 6-month, and 1-year area under the curves of the CEUS-clinical nomogram, clinical nomogram, and TNM staging system were 0.518, 0.552, and 0.843 versus 0.354, 0.240, and 0.624 (P = .048, .049, and .471) vs. 0.562, 0.545, and 0.843 (P = .630, .564, and .007), respectively. The calibration curves of the CEUS-clinical model at different prediction time pionts were all close to the ideal line. The CEUS-clinical model effectively stratified patients into groups of high and low risk of recurrence in both training and validation set, while the TNM staging system only works on the training set.

CONCLUSIONS: Our CEUS-clinical nomogram is a reliable early recurrence prediction tool for hepatocellular-cholangiocarcinoma and helps postoperative risk stratification.

来源:J Ultrasound Med,查看原文。版权归原作者所有。

引用

  1. Guo, Lu, Hu, et al. Contrast-Enhanced Ultrasound-Based Nomogram: A Potential Predictor of Individually Postoperative Early Recurrence for Patients With Combined Hepatocellular-Cholangiocarcinoma. J Ultrasound Med. 2021. PMID: 34751450. doi:10.1002/jum.15869

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。